Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

NCT03123588 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

12

Enrollment

INDUSTRY

Sponsor class

Stopped Enrollment issues

Conditions

MPN (Myeloproliferative Neoplasms)

Interventions

DRUG: Ruxolitinib
DRUG: Anagrelide
DRUG: Placebo
DRUG: Placebo

Sponsor

Incyte Corporation